David Filmore

20 Years of Experience

About

@MedtechDavid, Executive Editor of MedTech Strategist Market Pathways has been covering the medical technology sector as a writer and editor for about 20 years. David specializes in the regulatory and reimbursement dynamics that impact device and diagnostics companies' ability to succeed in the marketplace. He joined MedTech Strategist in 2019 to launch Market Pathways as the premier publication covering policy and market access issues in medtech.

David previously served as the executive editor/editor-in-chief of The Gray Sheet and Medtech Insight, and he spent years as a writer for The Gray Sheet, reporting on policies impacting the device industry from FDA, CMS, OIG, Europe, and elsewhere around the world. He frequently talks to leaders in government and industry and enjoys digging into the details of developing healthcare policies to understand how they will play out in the market. Earlier in his career, David was an editor with the American Chemical Society, where he analyzed issues for professionals in the pharmaceutical industry and analytical instrumentation space. He has also worked in the drug industry and has a degree in chemistry.

Specialties
Publications
Articles from David Filmore:
Read all from this author
Regulatory & Reimbursement

What’s Happening at CDRH? RIFs, Retirements, User Fees, and Unknowns

  • 2025-04-28 00:00:00.0
  • David Filmore
  • Market Pathways

FDA’s device center lost more than 200 people in the large-scale reduction-in-force action advanced April 1, and many more have left in a steady stream of retirements and resignations under pressure by the Trump administration. Here’s a roundup of what we know about the people and functions lost at CDRH, and possible next shoes to drop, including review impacts, user-fee program risks, and the prospects of a broader reorganization. (Pictured: Building 66 on FDA's White Oak Campus)

Read Article